Viridian Therapeutics Inc (NASDAQ: VRDN) kicked off on Tuesday, down -5.13% from the previous trading day, before settling in for the closing price of $17.14. Over the past 52 weeks, VRDN has traded in a range of $9.90-$27.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 31.28%. While this was happening, its average annual earnings per share was recorded -8.15%. With a float of $73.61 million, this company’s outstanding shares have now reached $81.59 million.
Let’s determine the extent of company efficiency that accounts for 143 employees. In terms of profitability, gross margin is -1858.28%, operating margin of -111591.06%, and the pretax margin is -102092.38%.
Viridian Therapeutics Inc (VRDN) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Viridian Therapeutics Inc is 9.78%, while institutional ownership is 103.44%. The most recent insider transaction that took place on Sep 27 ’24, was worth 117,050. In this transaction Chief Operating Officer of this company bought 5,000 shares at a rate of $23.41, taking the stock ownership to the 6,000 shares. Before that another transaction happened on Sep 27 ’24, when Company’s President and CEO bought 21,400 for $23.33, making the entire transaction worth $499,262. This insider now owns 21,400 shares in total.
Viridian Therapeutics Inc (VRDN) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -8.15% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.32% during the next five years compared to 31.28% growth over the previous five years of trading.
Viridian Therapeutics Inc (NASDAQ: VRDN) Trading Performance Indicators
Take a look at Viridian Therapeutics Inc’s (VRDN) current performance indicators. Last quarter, stock had a quick ratio of 19.49. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4422.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.05, a number that is poised to hit -1.01 in the next quarter and is forecasted to reach -3.80 in one year’s time.
Technical Analysis of Viridian Therapeutics Inc (VRDN)
Looking closely at Viridian Therapeutics Inc (NASDAQ: VRDN), its last 5-days average volume was 0.73 million, which is a drop from its year-to-date volume of 0.92 million. As of the previous 9 days, the stock’s Stochastic %D was 78.82%.
During the past 100 days, Viridian Therapeutics Inc’s (VRDN) raw stochastic average was set at 83.36%, which indicates a significant increase from 65.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.85 in the past 14 days, which was higher than the 0.82 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.43, while its 200-day Moving Average is $17.54. However, in the short run, Viridian Therapeutics Inc’s stock first resistance to watch stands at $17.08. Second resistance stands at $17.90. The third major resistance level sits at $18.45. If the price goes on to break the first support level at $15.70, it is likely to go to the next support level at $15.15. Should the price break the second support level, the third support level stands at $14.33.
Viridian Therapeutics Inc (NASDAQ: VRDN) Key Stats
The company with the Market Capitalisation of 1.33 billion has total of 81,592K Shares Outstanding. Its annual sales at the moment are 300 K in contrast with the sum of -269,950 K annual income. Company’s last quarter sales were recorded 70 K and last quarter income was -86,910 K.
